The Secret Social Lives of Bacteria

Mention bacteria to most people and the reaction is predictable: a grimace, maybe a reach for hand sanitizer. We’ve been trained to think of them as tiny troublemakers—invisible, indiscriminate, best eliminated.

But researchers at Yale School of Medicine (YSM) are revealing a far more complicated picture. Bacteria have rich social lives. They build electrical infrastructure, wage sophisticated chemical warfare, form unlikely alliances across species lines, and shape the very medications keeping us alive. Understanding their secret world, it turns out, may be one of the most consequential frontiers in modern medicine.

To understand what bacteria are actually doing inside their communities, Nikhil Malvankar, PhD, associate professor of molecular biophysics and biochemistry, reaches for an unlikely analogy: a high-rise apartment complex.

Many of the bacteria he studies are anaerobic, meaning they can’t use oxygen to breathe the way we do. Like humans, they break down food, generating protons and electrons in the process. The protons make energy. But the electrons have to go somewhere, and when the nearest electron acceptor might be thousands of times a bacterium’s own body length away, disposal becomes a challenge.

Some bacteria found an elegant solution. They grow on top of each other, layer upon layer, and construct protein nanowires—microscopic filaments that function as biological electrical cables—to shuttle electrons across extraordinary distances. “The bacteria living on the 500th floor can still transfer electrons all the way to the first floor,” Malvankar explains. “They’ve created an electrical power grid, and every bacterium has access to it.”

What makes this more remarkable is the physics. Malvankar’s lab discovered that these nanowires don’t move electrons the way most biological molecules do—passing a single charge from one molecule to the next like a slow relay race. Instead, they pack their wires with a sea of free electrons, functioning more like copper wire than anything previously observed in biology.

The proof came from a counterintuitive experiment: When the team cooled the nanowires down, electron transfer actually sped up. In conventional biology, cooling slows reactions. But in a copper wire, cooling reduces interference and electrons move more freely. The bacteria’s wires behaved the same way.

“The way these bacteria have constructed their communication channels is fundamentally different from anything else we’ve seen in biology,” Malvankar says. “That’s the secret of their survival.”

The wired bacteria, his experiments show, dominate competitors that lack this infrastructure. They attach where they want, gain more energy, and grow more robustly. Unwired rivals get washed out or die. It is, in a very real sense, a decisive advantage. But that infrastructure also creates a vulnerability: Disrupt the electron export system, and bacteria can’t grow. Malvankar is exploring exactly that—using electric and magnetic fields, light, and temperature changes to manipulate bacterial electron flow, either inhibiting pathogens or accelerating beneficial microbes.

While Malvankar’s bacteria are building power grids, others have spent billions of years perfecting something altogether different: weapons.

Joseph Mougous, PhD, Enders Professor of Microbial Pathogenesis and a Howard Hughes Medical Institute Investigator, studies the molecular mechanisms by which bacteria attack, poison, and eliminate their rivals—and the defenses they’ve evolved to survive being targeted in return. “Bacteria have been engaged in fierce competition with each other for at least 3 billion years,” he says. “It is not surprising that they have evolved a diverse array of sophisticated mechanisms for interbacterial antagonism.”

What does that battlefield actually look like? Mougous is candid about the difficulty of seeing it directly. Visualizing bacterial communities in their natural state remains technically challenging, and microbiologists have often had to infer behavior from biomarkers, modeling, and genomics. When sophisticated imaging techniques do capture still images of microbial communities, what researchers typically see are bacteria clustered in small groups alongside neighboring clusters of different species, suggesting that bacteria of different types tend not to mix peaceably.

“At some point, perhaps simply due to physical segregation, there are most certainly periods of truce,” Mougous says. “But my guess is that bacteria rarely, if ever, let their guard down—a potential colonizer of their niche could come floating by at any time.”

The weapon Mougous has studied most extensively is the type VI secretion system, or T6SS. It’s a molecular device that bacteria use to inject toxins directly into neighboring cells on contact. Comparing it to a spear gun, he says, is apt. At the molecular level, the T6SS is structurally related to a bacteriophage tail—bacteria have essentially co-opted a virus-like puncturing device and repurposed it to deliver lethal proteins into rivals. The firing event is extraordinarily fast, on the order of milliseconds, and a single injection typically delivers a cocktail of different toxins. If the target cell lacks immunity factors or cannot mount an adequate defense, the attack is lethal.

Crucially, every bacterium that produces these toxins must also protect itself from them. “If you produce a toxin, you need to protect yourself and neighboring kin cells from it,” Mougous explains.

Bacteria using the T6SS always encode immunity proteins alongside their toxins. But defense goes further still. Mougous’s lab has discovered that bacteria possess “danger sensing” mechanisms—the ability to detect when they are under attack—and respond with a coordinated counteroffensive that activates both defensive and offensive pathways simultaneously.

“If either the defensive or offensive arm of this response is compromised,” he says, “the cell is far more likely to be eliminated.” Every bacterium, in other words, must function as both warrior and fortress at once.

The arms race this creates has been running for billions of years and shows no sign of a winner. “New toxins evolve, new defense mechanisms follow, and the result is the extraordinary diversity of antagonistic systems we observe,” Mougous says. His lab continues to uncover toxin families and toxin delivery mechanisms with no resemblance to anything previously described, including a recent discovery in Streptomyces, bacteria that researchers have studied for over a century. They found that large particles secreted by Streptomyces blocked competing species by a mechanism entirely unlike any known antibacterial system.

“Every time we look carefully, we find new remarkable ways bacteria employ to antagonize each other,” he says.

If bacteria are waging war in the soil and ocean floor, the community living inside us is no less turbulent. Andrew Goodman, PhD, chair and C.N.H. Long Professor of Microbial Pathogenesis, thinks of the gut microbiome less like a city and more like a jungle.

“These microbes are closely monitoring who’s around them and have multiple ways—cooperative and antagonistic—of connecting with their neighbors,” he says. The density of the ecosystem is staggering: trillions of microbes in the equivalent of a drop of water, carrying more than a hundred times the number of genes found in the entire human genome.

Meanwhile, Mougous’s research has shown that the T6SS is widespread in the human gut, operating continuously among the Bacteroidales that dominate our intestinal communities. “These battles are probably shaping the composition of your gut microbiome right now,” Mougous says. “The outcomes of these fights influence which strains persist and which get displaced. That matters for health because the composition of your microbiome affects everything from nutrient metabolism to immune function to susceptibility to pathogens.”

The gut community also bears the scars of its history. Goodman’s lab has shown that serious infection leaves a lasting genetic mark on the bacteria that survive—not just shifting which species are present, but driving changes within species as the inflammatory environment selects for variants that replace the original population and persist long after the infection clears.

“We think about this not only at the level of the community,” Goodman explains, “but even within a species, how a variant can replace something that was there based on the altered selection that happens during infection.”

The enormous genetic capacity in the gut microbiome, more than a hundred times that of the human genome, also means gut bacteria carry a staggering number of enzymes capable of chemically transforming whatever passes through the digestive system—including medications.

“Microbes don’t recognize those molecules as drugs,” Goodman explains. “To them, they are potentially nutrients, electron receptors, or something to be dismantled.” The consequences range from altering a drug’s potency to generating toxic byproducts that would never appear otherwise.

Recent research from Goodman’s lab illustrates a striking example involving two widely used drugs for Parkinson’s disease. One drug disrupts the microbiome in a way that encourages the growth of a specific microbe that then targets and metabolizes the second Parkinson’s drug. The two medications interacted with each other through the microbiome as an intermediary. In another recent paper, his team showed that certain drugs alter the microbiome in ways that dampen immune response, leaving patients more vulnerable to infection.

For Goodman, the more accurate framing isn’t adversarial, it’s evolutionary. “As long as there’s been a gut, there’s been microbes in it,” he says. The relationship between humans and our microbial communities is ancient and largely mutual: a warm, protected home for bacteria that, in return, help prevent infection, guide immune development, and perform biological functions we are only beginning to catalogue.

The microbiome isn’t crashing the prescription as an uninvited guest—it has simply always been there, and medicine is only now catching up to that reality. “Predicting why a drug works for one person and not another, or why it causes side effects in one and not another, may well require understanding what gut microbes are doing to the drugs, and what the drugs are doing to those microbes.”

The deeper question animating all three researchers is whether this knowledge can be turned into intervention: Can we learn to deliberately reshape bacterial communities for human benefit?

Mougous has already demonstrated proof of concept. His lab engineered T6SS-producing bacteria with programmable adhesion proteins, allowing them to selectively bind and kill specific bacterial species within a mixed community, eliminating a target organism from a diverse mixture without broadly disrupting everything else. “More work is needed,” he acknowledges, “but this points toward a viable way to precisely target pathogens in the context of a human infection.” It’s a potential alternative to conventional antibiotics, which kill indiscriminately and leave the microbiome in disarray.

Goodman points to fecal microbiome transplantation—giving patients a microbiome from a healthy individual—as evidence that reshaping bacterial communities can already treat disease. It is now standard care for people who have recurrent Clostridioides difficile (C. diff) infection and it works with striking reliability.

Looking further ahead, he sees potential for microbiome manipulation in cancer immunotherapy, autoimmune disease, and personalized drug response. “It’s not crazy to think about temporarily altering someone’s microbiome so they could tolerate a drug, or respond to a drug, that they otherwise couldn’t use.”

Malvankar’s vision extends further still. The same bacteria that run electrical networks underground are among Earth’s most efficient methane consumers, capturing roughly 80% of the methane they encounter. His lab has identified conditions that prompt these bacteria to produce more nanowires, accelerating methane consumption, and has found ways to reverse the process entirely, flipping the direction of electron flow so that methane-producing bacteria begin consuming it instead. “Electrons are still electrons,” he says. “The same rules of physics apply whether they’re in a copper wire or a bacterium. That gives us a new level of control.”

What emerges from conversations with these researchers is less a story about germs than a story about humility. Bacteria have been solving hard problems—long-distance electrical communication, community defense, chemical synthesis—for billions of years. We have been paying attention for a fraction of that time.

“Humans learned how to send electricity over a long distance only about 100 years ago,” Malvankar says. “These bacteria have been doing it since the beginning. Nature is way, way smarter than us.”

Mougous frames the same idea through the lens of discovery: Researchers have studied Streptomyces for more than a century, mining it for antibiotics, and only now are finding weapons systems that were there all along, entirely undetected. The more carefully scientists look, the more they find.

Goodman, who works at the intersection of microbiology and medicine, sees a field poised for transformation. A hundred times more genes than the human genome, packed into a community living inside each of us—and we are only beginning to understand what they do, what they say to one another, and what they might do for us, if we learn to listen.

The bacteria, it turns out, have had a great deal to tell us all along.